Eliem Therapeutics, Inc. (ELYM): Price and Financial Metrics
ELYM Price/Volume Stats
| Current price | $3.98 | 52-week high | $5.19 |
| Prev. close | $3.39 | 52-week low | $2.34 |
| Day low | $3.32 | Volume | 580,200 |
| Day high | $4.16 | Avg. volume | 568,109 |
| 50-day MA | $3.06 | Dividend yield | N/A |
| 200-day MA | $2.78 | Market Cap | 110.32M |
ELYM Stock Price Chart Interactive Chart >
Eliem Therapeutics, Inc. (ELYM) Company Bio
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Latest ELYM News From Around the Web
Below are the latest news stories about ELIEM THERAPEUTICS INC that investors may wish to consider to help them evaluate ELYM as an investment opportunity.
Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers for Friday! |
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday. |
Why Is BioSig Technologies (BSGM) Stock Up 19% Today?BioSig Technologies (BSGM) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NVDA) Inception program. |
Why Is Discover Financial (DFS) Stock Down 13% Today?Discover Financial (DFS) stock is falling on Thursday after the financial services company revealed it's undergoing a regulatory review. |
ELYM Price Returns
| 1-mo | 44.20% |
| 3-mo | 38.43% |
| 6-mo | 53.08% |
| 1-year | 28.39% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 47.41% |
| 2023 | -26.43% |
| 2022 | -64.91% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...